NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]TargetActionsOrganismUHLA class I histocompatibility antigen, A-2 alpha chainHumansUHLA class I histocompatibility antigen, A-3 alpha chainHumans
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
Online Inquiry
CONTACT US
For more information on how our products could help advance your project, please contact us.